Kyntra Bio Inc (NASDAQ:KYNB) Stock Has Consensus Target Price of $36.80

Shares of Kyntra Bio Inc (NASDAQ:KYNB) have been assigned an average rating of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a sell rating and five have given a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $36.80.

A number of equities analysts have recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $43.00 price objective on shares of Kyntra Bio in a research note on Tuesday, September 1st. Weiss Ratings upgraded Kyntra Bio from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Zacks Research downgraded shares of Kyntra Bio from a “hold” rating to a “strong sell” rating in a report on Monday, October 12th. Lake Street Capital began coverage on Kyntra Bio in a report on Thursday, September 17th. They set a “buy” rating and a $41.00 target price on the stock. Finally, Maxim Group started coverage on Kyntra Bio in a research report on Tuesday, October 13th. They set a “buy” rating and a $35.00 price target for the company.

Institutional Investors Weigh In On Kyntra Bio

A hedge fund recently bought a new stake in Kyntra Bio stock. ADAR1 Capital Management LLC bought a new stake in shares of Kyntra Bio Inc (NASDAQ:KYNB) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 10,469 shares of the company’s stock, valued at approximately $71,000. ADAR1 Capital Management LLC owned approximately 0.26% of Kyntra Bio at the end of the most recent reporting period. 72.71% of the stock is currently owned by institutional investors.

Kyntra Bio Stock Performance

Kyntra Bio stock opened at $3.73 on Friday. The company has a market capitalization of $15.11 million, a PE ratio of 0.08 and a beta of 1.08. The company has a 50 day moving average price of $6.29 and a 200-day moving average price of $7.00. Kyntra Bio has a fifty-two week low of $3.60 and a fifty-two week high of $11.39.

Kyntra Bio Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.